Wednesday, December 3, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Consumer & Luxury

Coca-Cola Faces Potential Billion-Dollar Write-Down on Costa Coffee Investment

Robert Sasse by Robert Sasse
August 31, 2025
in Consumer & Luxury, Earnings, Mergers & Acquisitions, Turnaround
0
Coca-Cola Stock
0
SHARES
219
VIEWS
Share on FacebookShare on Twitter

Coca-Cola’s ambitious 2018 acquisition of British coffee chain Costa Coffee for $5 billion appears to be heading toward a costly conclusion. The beverage giant, which purchased the coffeehouse chain as a strategic move to capture market share in the lucrative coffee sector, is now reportedly considering a sale that could result in substantial financial losses.

Strategic Review Underway

According to recent reports, Coca-Cola has engaged investment bank Lazard to evaluate strategic alternatives for Costa Coffee, including a potential divestiture to private equity firms or other interested parties. This development follows CEO James Quincey’s July admission that the Costa investment had failed to deliver anticipated returns.

Market analysts estimate that Costa Coffee’s current valuation may have fallen to approximately half of its original purchase price. Such a valuation would translate to a roughly $2.5 billion loss for Coca-Cola, representing a significant setback to the company’s diversification strategy beyond its traditional soft drink portfolio.

Should investors sell immediately? Or is it worth buying Coca-Cola?

Market Response and Unrelated Speculation

Financial markets showed limited reaction to the potential divestiture news. Stock performance received some support from unconfirmed reports—previously circulated by former President Trump—suggesting Coca-Cola might transition to cane sugar in its U.S. products. The company has not verified these claims.

The original acquisition was intended to strengthen Coca-Cola’s competitive position against rivals like Starbucks while establishing a foothold in the hot beverage market. A sale at a substantial loss would mark a notable strategic reversal, potentially signaling a renewed focus on the company’s core beverage business.

Timeline and Broader Context

Initial bids for Costa Coffee are expected to emerge this autumn. Investors will be monitoring developments closely, particularly as recent quarterly results revealed underlying challenges. Despite implementing price increases, Coca-Cola reported a 1% decline in global sales volume. The company’s upcoming October earnings release is anticipated to provide further insight into its strategic direction regarding the coffee chain and broader business priorities.

Ad

Coca-Cola Stock: Buy or Sell?! New Coca-Cola Analysis from December 3 delivers the answer:

The latest Coca-Cola figures speak for themselves: Urgent action needed for Coca-Cola investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 3.

Coca-Cola: Buy or sell? Read more here...

Tags: Coca-Cola
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Ballard Power Stock
Analysis

Is Ballard Power Stock Nearing an Inflection Point?

December 3, 2025
Bionxt Solutions Stock
Analysis

Bionxt Solutions Secures Key Licensing Deal in Cancer Therapy Market

December 3, 2025
European Lithium Stock
Commodities

Strategic Moves and Sector Momentum: European Lithium Navigates Shareholder Shifts and Capital Strategy

December 3, 2025
Next Post
Strategy Stock

Bitcoin Billions Fuel Unprecedented Dividend Strategy

Unitedhealth Stock

UnitedHealth Shares Surge Following Major Investment from Buffett

James Hardie Industries Stock

James Hardie Shares Plummet Amid Perfect Storm of Challenges

Recommended

Capital One Stock

Major Institutions Back Capital One Despite Acquisition Costs

3 months ago
Coca-Cola Stock

Coca-Cola Stock: A Dual-Pronged Growth Strategy Takes Shape

1 week ago
Summit Therapeutics Stock

Summit Therapeutics: Clinical Data Divides Market as CEO Backs Conviction

3 months ago
SunHydrogen Stock

SunHydrogen Reaches Commercial Milestone with First Revenue

3 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Bionxt Solutions Secures Key Licensing Deal in Cancer Therapy Market

Strategic Moves and Sector Momentum: European Lithium Navigates Shareholder Shifts and Capital Strategy

Netflix Stock: Aggressive Expansion Strategy Takes Shape

Is Innovative Industrial Properties a Deep-Value Cannabis Play?

Is Alibaba’s Stock Dip a Strategic Entry Point?

Intellia Therapeutics Faces Critical Juncture Following Clinical Trial Death

Trending

Novo Nordisk Stock
Analysis

Novo Nordisk Faces Critical Juncture Amid Legal and Competitive Pressures

by Robert Sasse
December 3, 2025
0

The year 2025 is shaping up to be a formidable challenge for Novo Nordisk, with its share...

Ballard Power Stock

Is Ballard Power Stock Nearing an Inflection Point?

December 3, 2025
Redcare Pharmacy Stock

Redcare Pharmacy Shares Continue Their Steep Descent

December 3, 2025
Bionxt Solutions Stock

Bionxt Solutions Secures Key Licensing Deal in Cancer Therapy Market

December 3, 2025
European Lithium Stock

Strategic Moves and Sector Momentum: European Lithium Navigates Shareholder Shifts and Capital Strategy

December 3, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Novo Nordisk Faces Critical Juncture Amid Legal and Competitive Pressures
  • Is Ballard Power Stock Nearing an Inflection Point?
  • Redcare Pharmacy Shares Continue Their Steep Descent

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com